Key Takeaways: Modern precision oncology requires both molecular imaging (via 68Ga PET/CT scans) and accurate tissue sampling (via CT-guided or USG-guided FNAC biopsy). These two modalities are not competitive — they are profoundly complementary. PET/CT identifies the biological behaviour and distribution of disease; biopsy provides the cellular and molecular diagnosis needed to select therapy. Neurad Diagnostics offers both services under one roof, enabling a fully integrated, same-centre diagnostic pathway that accelerates the journey from suspicion to treatment.
Why Precision Cancer Diagnosis Requires Both Imaging and Biopsy
Precision cancer diagnosis in the modern era is a two-part process. The first part is molecular imaging — identifying where disease is located, how biologically active it is, and whether it expresses specific molecular targets relevant to therapy selection. The second part is tissue diagnosis — obtaining cellular or histological material from the disease to establish the pathological type, grade, receptor status, and molecular profile that define the treatment strategy. Neither part is sufficient alone. Imaging without tissue cannot establish the diagnosis or guide targeted therapy selection. Tissue without comprehensive imaging cannot identify all disease sites or select the optimal lesion for biopsy.
The integration of 68Ga PET/CT imaging with image-guided biopsy — both CT-guided FNAC biopsy and USG-guided FNAC biopsy — is the foundation of the diagnostic pathway at Neurad Diagnostics. Our in-house 68Ga Gallium Generator produces daily fresh radiopharmaceuticals (Dotanoc, PSMA, FAPI, Exendin, and Trivehexin) for molecular imaging, while our interventional radiology team performs precision CT-guided and USG-guided biopsies of any lesion identified on imaging. The result is a genuinely integrated diagnostic centre where the imaging and pathological diagnosis are co-ordinated in one place.
The Clinical Synergy Between 68Ga PET/CT and Image-Guided Biopsy
Using PET/CT to Guide Biopsy Site Selection: PET-Directed Biopsy
One of the most powerful applications of the PET/CT–biopsy combination is PET-directed biopsy: using metabolic and molecular data from 68Ga PET/CT to identify the most diagnostically appropriate lesion for sampling and the most biologically active portion of that lesion. This concept addresses a fundamental problem in cancer biopsy: spatial intratumoural heterogeneity. Large tumours frequently contain zones of necrosis, fibrosis, and viable tumour in close proximity. A biopsy needle entering the central necrotic zone will yield non-diagnostic material; a needle directed by PET/CT to the area of highest molecular tracer uptake will sample the most biologically representative, viable tissue.
At Neurad Diagnostics, our interventional radiologists routinely review PET/CT images prior to planning CT-guided or USG-guided biopsy procedures. For heterogeneous lesions, PET data is co-registered with diagnostic CT to identify the optimal biopsy zone. This PET-directed approach is particularly valuable in: large hepatic metastases with central necrosis; heterogeneous lung masses; post-treatment lymphoma nodes with residual FDG or FAPI activity suggesting viable disease; and bone lesions where lytic and sclerotic zones may have different pathological significance.
PET/CT-Identified Metastases That Require Biopsy Confirmation
68Ga PET/CT is a powerful staging tool, but it is not infallible. False-positive findings can occur when physiological processes mimic tumour uptake — for example, inflammatory lymph nodes showing FAPI activity, or granulomatous disease (sarcoidosis, tuberculosis) displaying DOTANOC uptake in some cases. When a 68Ga PET/CT identifies lesions that change the patient’s staging or treatment eligibility — such as suspected metastatic lymph nodes that would preclude curative surgery, or a distant metastasis that would indicate systemic rather than local therapy — histological confirmation via CT-guided or USG-guided FNAC biopsy is often essential before irrevocably committing a patient to a palliative treatment pathway.
At Neurad Diagnostics, we are equipped to perform both the PET/CT imaging and the confirmatory biopsy in the same facility, with co-ordinated scheduling that minimises the total elapsed time between imaging, biopsy, and pathological result. For time-sensitive oncological decisions — such as whether a patient is eligible for neoadjuvant chemotherapy before surgery — this integrated capability can reduce the diagnostic pathway from weeks to days.
Case Scenarios: When PET/CT and Biopsy Are Both Required
Scenario 1: Newly Diagnosed Lung Mass with Suspected Mediastinal Adenopathy
A patient presents with a right upper lobe lung mass and enlarged mediastinal lymph nodes on CT. FAPI PET/CT is performed at Neurad Diagnostics, demonstrating intense FAPI uptake in both the primary lesion and multiple mediastinal nodes — consistent with N2/N3 mediastinal involvement. The staging information changes the treatment plan from surgical resection to concurrent chemoradiotherapy. However, before committing to non-surgical treatment, histological confirmation of the mediastinal nodes is obtained via CT-guided core needle biopsy — performed at Neurad Diagnostics on the following day. The biopsy confirms metastatic adenocarcinoma with EGFR mutation — information that enables targeted therapy with an EGFR inhibitor rather than standard chemotherapy.
Scenario 2: Elevated PSA After Prostatectomy — PSMA PET/CT and Prostate Bed Biopsy
A 65-year-old man with rising PSA (0.6 ng/mL) 18 months after radical prostatectomy undergoes PSMA PET scan at Neurad Diagnostics. The scan identifies a small focus of PSMA avidity in the prostate bed — consistent with local recurrence. No pelvic nodal or distant metastatic disease is identified. This localised recurrence pattern supports a salvage radiotherapy approach. However, the radiation oncologist requests histological confirmation of viable disease before proceeding with salvage RT. CT-guided core biopsy of the prostate bed lesion is performed at Neurad Diagnostics under careful CT guidance, yielding a histologically confirmed recurrent acinar adenocarcinoma — allowing the salvage radiotherapy to proceed with confidence.
Scenario 3: Hepatic Lesions on DOTANOC PET/CT — Confirming NET Metastases vs. Benign Aetiology
A patient with previously resected ileal neuroendocrine tumour undergoes surveillance Dotanoc PET scan at Neurad Diagnostics. Two new hepatic lesions are detected with moderate DOTANOC uptake. The imaging appearance is consistent with NET metastases, but atypical features raise the possibility of haemangioma with incidental mild SSTR expression. Rather than initiating PRRT on imaging findings alone, the gastroenterologist requests USG-guided liver biopsy of the larger lesion — performed at Neurad Diagnostics. Histology confirms NET metastases with Grade 2 morphology and SSTR2 overexpression on IHC, confirming the patient’s suitability for PRRT. Therapy proceeds promptly based on the integrated imaging and pathological assessment.
CT-Guided vs. USG-Guided Biopsy After PET/CT: Making the Right Choice
Once a 68Ga PET/CT scan has identified the optimal target lesion for biopsy, the next decision is the guidance modality: CT-guided FNAC biopsy or USG-guided FNAC biopsy. Both are available at Neurad Diagnostics, and the choice is determined by the anatomical location of the target, the ultrasound visibility of the lesion, and the technical characteristics of the planned needle trajectory.
Ultrasound guidance is preferred for: superficial lesions accessible via a clear sonographic window (thyroid, breast, superficial lymph nodes, subcutaneous masses); intra-abdominal lesions with a good acoustic window (anterior liver, kidney, accessible pancreatic tail); and situations where radiation avoidance is important. CT guidance is preferred for: deep retroperitoneal or pelvic lesions; posterior mediastinal masses; bone lesions; lesions adjacent to major vessels requiring three-dimensional trajectory planning; and any scenario where ultrasound visualisation is impaired by overlying bone, bowel gas, or adipose tissue.
Our interventional radiologists at Neurad Diagnostics review each case pre-procedure with the dual perspective of the PET/CT findings and the anatomical biopsy planning requirements, ensuring the optimal guidance modality is selected for each individual patient.
Molecular Profiling: Maximising Biopsy Value
In the era of precision oncology, a biopsy is not merely a diagnostic exercise — it is the first step in a comprehensive molecular profiling programme that determines which of the rapidly expanding portfolio of targeted therapies is most likely to benefit the individual patient. At Neurad Diagnostics, our CT-guided and USG-guided biopsy specimens are collected and handled carefully to ensure compatibility with the required molecular analyses.
Standard histopathological assessment (morphology, IHC) is complemented by molecular profiling where indicated: EGFR, KRAS, BRAF, ALK, ROS1 mutation testing for lung cancer; HER2 amplification analysis for breast and gastric cancer; BRCA1/2 germline and somatic testing for breast, ovarian, and pancreatic cancer; MSI/MMR status for colorectal cancer and pan-tumour immunotherapy eligibility; and PD-L1 expression for immunotherapy eligibility. All molecular testing requirements are discussed with the referring oncologist at the time of biopsy planning to ensure adequate specimen volume and tissue handling protocols are implemented from the moment of needle sampling.
The Neurad Diagnostics Integrated Diagnostic Pathway: From First Symptom to Treatment Plan
Step 1: Clinical Referral and Imaging Strategy Discussion
The integrated diagnostic pathway at Neurad Diagnostics begins when a referring clinician — oncologist, surgeon, gastroenterologist, urologist, or general physician — contacts our team with a clinical query. Our nuclear medicine and interventional radiology physicians are available for direct pre-referral consultation to advise on the most appropriate imaging and biopsy strategy for the individual clinical scenario. This upfront consultation ensures that the right investigations are selected in the right sequence, minimising delays and redundant investigations.
Step 2: 68Ga PET/CT Imaging
The appropriate 68Ga PET/CT scan (Dotanoc, PSMA, FAPI, Exendin, or Trivehexin) is performed using tracer from our in-house Gallium Generator, on a date agreed with you when you book. Our nuclear medicine physicians review the scan in real time and communicate urgent findings immediately to the referring team. Reception will confirm when your report will be ready at the time of booking.
Step 3: Biopsy Planning Using PET/CT Data
Where tissue diagnosis is required — either as the next investigation or as a confirmatory step following PET/CT staging — our interventional radiologists use the PET/CT dataset as a road map for biopsy planning. The optimal lesion, the optimal zone within that lesion, and the optimal needle trajectory are defined using co-registered PET/CT and diagnostic CT data. CT-guided or USG-guided FNAC biopsy is then scheduled, and the date is confirmed with you in advance.
Step 4: Specimen Processing and Molecular Profiling
Biopsy specimens are sent to an accredited pathology laboratory, with the specific molecular profiling requirements pre-specified at the time of procedure planning. Histopathology, IHC and molecular testing results are communicated to the referring team as they become available.
Step 5: Multidisciplinary Team Discussion and Treatment Planning
The combined PET/CT staging information and pathological diagnosis from biopsy provides the multidisciplinary team with everything needed to make a fully informed, guideline-compliant treatment recommendation for the patient. Our nuclear medicine and interventional radiology physicians are available to attend MDT meetings virtually or in person to discuss complex cases, and our detailed structured reports are designed to be directly incorporated into MDT documentation.
Liquid Biopsy vs. Tissue Biopsy: Where Image-Guided Biopsy Remains Irreplaceable
The advent of liquid biopsy — the detection of circulating tumour DNA (ctDNA) in blood — has generated much interest as a non-invasive alternative to tissue sampling. Liquid biopsy has genuine clinical utility for monitoring treatment response and detecting resistance mutations in patients with established diagnoses on systemic therapy. However, it has significant limitations as a diagnostic tool for initial pathological classification: it cannot provide tissue architecture for tumour grading, is insufficient for receptor status assessment in many cancers, and has lower sensitivity for early-stage or localised disease compared to tissue biopsy.
CT-guided FNAC biopsy and USG-guided FNAC biopsy remain irreplaceable for the initial pathological diagnosis of a newly detected lesion, for confirming disease progression at a specific anatomical site, and for obtaining adequate material for molecular profiling at an accredited laboratory. Liquid biopsy complements tissue biopsy in established cases; it does not replace the precision image-guided biopsy in the initial diagnostic workup of most cancers.
Frequently Asked Questions: Integrated PET/CT Imaging and Biopsy at Neurad Diagnostics
Can I have my PET/CT scan and biopsy on the same day?
In selected cases, same-day PET/CT imaging and biopsy can be arranged at Neurad Diagnostics when the clinical situation demands the fastest possible diagnostic pathway. However, in most cases, the PET/CT scan is performed first to identify the optimal biopsy target and plan the procedure, with the biopsy scheduled afterwards. Your referring clinician and our interventional radiology team will advise on the optimal scheduling for your specific case.
Which 68Ga scan should be done before biopsy?
The appropriate 68Ga scan depends entirely on the suspected or confirmed tumour type. Dotanoc for suspected NETs, PSMA for prostate cancer, FAPI for gastrointestinal or hepatobiliary tumours, Exendin for suspected insulinoma, and Trivehexin for gliomas. In cases of uncertain primary diagnosis, FAPI PET/CT is often the most broadly applicable first-line scan because of its pan-tumour sensitivity. Our nuclear medicine consultants are available to advise on scan selection for any complex case.
Does having a PET scan affect the biopsy result?
The radiopharmaceuticals used in 68Ga PET scans do not affect the cellular or molecular composition of the biopsied tissue in a way that would influence pathological interpretation. The radiation dose delivered to the lesion from the PET scan is extremely low — many orders of magnitude below the threshold that could cause tissue changes. Standard intervals between the PET scan and biopsy (24–72 hours) are entirely safe and do not compromise specimen quality or diagnostic accuracy.
Related reading
- CT-guided FNAC and biopsy — confirming a lesion found on PET
- USG-guided FNAC and biopsy — when ultrasound guidance is enough
- The Gallium-68 generator — how the tracers are produced on site
- PET CT scan at Neurad — every tracer we run, with the rate for each study
Why Choose Neurad Diagnostics for Integrated Cancer Diagnosis
The integration of molecular PET/CT imaging and precision image-guided biopsy under one roof is not merely a logistical convenience — it is a clinical advantage with measurable impact on diagnostic accuracy, time to treatment initiation, and patient experience. At Neurad Diagnostics, we have built our entire diagnostic infrastructure around this integrated vision: an in-house 68Ga Gallium Generator for daily radiopharmaceutical production, a modern PET/CT scanner, an interventional radiology suite equipped for CT-guided and USG-guided biopsy procedures, and coordination with accredited pathology laboratories for histology and molecular profiling.
For patients facing a new cancer diagnosis or complex oncological evaluation, Neurad Diagnostics provides a coordinated imaging and biopsy pathway under one roof. For referring clinicians, we offer clear reporting and direct communication to support your clinical decision-making. Contact us today to discuss how our integrated precision cancer diagnosis services can support your next complex case.